StockData
Atossa Therapeutics, Inc. logo

Atossa Therapeutics, Inc. (ATOS) stock

ATOSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.90−0.03 (-1.55%)

Close on Nov 17, 2026Market cap $18.96MP/E –Yield –

Atossa Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Atossa Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$35.77M. For fiscal 2025 it was -$29.76M. The highest annual figure on record is -$3.49M in fiscal 2011.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$29.76M–
FY2024Dec 31, 2024-$21.03M–
FY2023Dec 31, 2023-$20.94M–
FY2022Dec 31, 2022-$20.76M–
FY2021Dec 31, 2021-$16.47M–
FY2020Dec 31, 2020-$11.57M–
FY2019Dec 31, 2019-$9.13M–
FY2018Dec 31, 2018-$8.96M–
FY2017Dec 31, 2017-$6.59M–
FY2016Dec 31, 2016-$5.37M–
FY2015Dec 31, 2015-$13.95M–
FY2014Dec 31, 2014-$10.56M–
FY2013Dec 31, 2013-$8.83M–
FY2012Dec 31, 2012-$3.90M–
FY2011Dec 31, 2011-$3.49M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.64M–
Q1 FY2026Mar 31, 2026-$9.58M–
Q4 FY2025Dec 31, 2025-$10.54M–
Q3 FY2025Sep 30, 2025-$6.01M–
Q2 FY2025Jun 30, 2025-$7.26M–
Q1 FY2025Mar 31, 2025-$5.96M–
Q4 FY2024Dec 31, 2024-$7.05M–
Q3 FY2024Sep 30, 2024-$4.75M–
Q2 FY2024Jun 30, 2024-$4.53M–
Q1 FY2024Mar 31, 2024-$4.70M–
Q4 FY2023Dec 31, 2023-$5.57M–
Q3 FY2023Sep 30, 2023-$3.88M–
Q2 FY2023Jun 30, 2023-$4.47M–
Q1 FY2023Mar 31, 2023-$7.02M–
Q4 FY2022Dec 31, 2022-$4.52M–
Q3 FY2022Sep 30, 2022-$5.41M–
Q2 FY2022Jun 30, 2022-$5.95M–
Q1 FY2022Mar 31, 2022-$4.88M–
Q4 FY2021Dec 31, 2021-$3.67M–
Q3 FY2021Sep 30, 2021-$3.06M–
Q2 FY2021Jun 30, 2021-$5.34M–
Q1 FY2021Mar 31, 2021-$4.41M–
Q4 FY2020Dec 31, 2020-$3.43M–
Q3 FY2020Sep 30, 2020-$2.68M–
Q2 FY2020Jun 30, 2020-$2.23M–
Q1 FY2020Mar 31, 2020-$3.23M–
Q4 FY2019Dec 31, 2019-$2.71M–
Q3 FY2019Sep 30, 2019-$1.77M–
Q2 FY2019Jun 30, 2019-$2.50M–
Q1 FY2019Mar 31, 2019-$2.15M–
Q4 FY2018Dec 31, 2018-$2.44M–
Q3 FY2018Sep 30, 2018-$2.30M–
Q2 FY2018Jun 30, 2018-$1.83M–
Q1 FY2018Mar 31, 2018-$2.39M–
Q4 FY2017Dec 31, 2017-$1.68M–
Q3 FY2017Sep 30, 2017-$1.70M-367.8%
Q2 FY2017Jun 30, 2017-$1.35M–
Q1 FY2017Mar 31, 2017-$1.86M–
Q4 FY2016Dec 31, 2016-$1.36M–
Q3 FY2016Sep 30, 2016$635.50K–

More Atossa Therapeutics figures

See a number that looks wrong?